APO Research
Talk to an analyst

APO RESEARCH · REPORT

GLP-1 Agonists for the Treatment of both Diabetes and Obesity

Compare research editions
View pricing & licenses

Selected research

Market Analysis & Forecast

Global GLP-1 Agonists for the Treatment of both Diabetes and Obesity Market Analysis and Forecast 2026-2032

27 December 2025197 pages

Choose your research edition.

Industry ResearchGLP-1 Agonists for the Treatment of both Diabetes and Obesity Industry Research Report 2026103 pages · $2,950 USDIndustry Growth & TrendsGlobal GLP-1 Agonists for the Treatment of both Diabetes and Obesity Industry Growth and Trends Forecast to 203263 pages · $3,450 USDMarket StructureGlobal GLP-1 Agonists for the Treatment of both Diabetes and Obesity Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032172 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal GLP-1 Agonists for the Treatment of both Diabetes and Obesity Market Outlook and Growth Opportunities 2026190 pages · $4,250 USDMarket Analysis & ForecastGlobal GLP-1 Agonists for the Treatment of both Diabetes and Obesity Market Analysis and Forecast 2026-2032197 pages · $4,950 USD

Market perspective

The global GLP-1 Agonists for the Treatment of both Diabetes and Obesity market is projected to grow from US$ million in 2026 to US$ million by 2032, at a Compound Annual Growth Rate (CAGR) of % during the forecast period.

The North America market for GLP-1 Agonists for the Treatment of both Diabetes and Obesity is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

Europe market for GLP-1 Agonists for the Treatment of both Diabetes and Obesity is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

Read the full market overview

Asia-Pacific market for GLP-1 Agonists for the Treatment of both Diabetes and Obesity is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

The China market for GLP-1 Agonists for the Treatment of both Diabetes and Obesity is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

The major global companies of GLP-1 Agonists for the Treatment of both Diabetes and Obesity include Novo Nordisk and Eli Lilly etc. In 2025, the world's top three vendors accounted for approximately % of the revenue.

Report Includes

This report presents an overview of global market for GLP-1 Agonists for the Treatment of both Diabetes and Obesity, market size. Analyses of the global market trends, with historic market revenue data for 2021 - 2025, estimates for 2026, and projections of CAGR through 2032.

This report researches the key producers of GLP-1 Agonists for the Treatment of both Diabetes and Obesity, also provides the revenue of main regions and countries. Of the upcoming market potential for GLP-1 Agonists for the Treatment of both Diabetes and Obesity, and key regions or countries of focus to forecast this market into various segments and sub-segments. Country specific data and market value analysis for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, Middle East, Africa, and Other Countries.

This report focuses on the GLP-1 Agonists for the Treatment of both Diabetes and Obesity revenue, market share and industry ranking of main manufacturers, data from 2021 to 2026. Identification of the major stakeholders in the global GLP-1 Agonists for the Treatment of both Diabetes and Obesity market, and analysis of their competitive landscape and market positioning based on recent developments and segmental revenues. This report will help stakeholders to understand the competitive landscape and gain more insights and position their businesses and market strategies in a better way.

This report analyzes the segments data by Type and by Application, revenue, and growth rate, from 2021 to 2032. Evaluation and forecast the market size for GLP-1 Agonists for the Treatment of both Diabetes and Obesity revenue, projected growth trends, production technology, application and end-user industry.

GLP-1 Agonists for the Treatment of both Diabetes and Obesity Segment by Company

Novo Nordisk

Eli Lilly

GLP-1 Agonists for the Treatment of both Diabetes and Obesity Segment by Type

Tirzepatide

Semaglutide

Liraglutide

GLP-1 Agonists for the Treatment of both Diabetes and Obesity Segment by Application

Retail Pharmacies

Hospital and Clinic

Other

GLP-1 Agonists for the Treatment of both Diabetes and Obesity Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global status and future forecast, involving growth rate (CAGR), market share, historical and forecast.

2. To present the key players, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify significant trends, drivers, influence factors in global and regions.

6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global GLP-1 Agonists for the Treatment of both Diabetes and Obesity market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of GLP-1 Agonists for the Treatment of both Diabetes and Obesity and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in market size), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of GLP-1 Agonists for the Treatment of both Diabetes and Obesity.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.

Chapter 2: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 3: Revenue of GLP-1 Agonists for the Treatment of both Diabetes and Obesity in global and regional level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.

Chapter 4: Detailed analysis of GLP-1 Agonists for the Treatment of both Diabetes and Obesity company competitive landscape, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.

Chapter 5: Provides the analysis of various market segments by type, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 6: Provides the analysis of various market segments by application, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 7: Provides profiles of key companies, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, GLP-1 Agonists for the Treatment of both Diabetes and Obesity revenue, gross margin, and recent development, etc.

Chapter 8: North America by type, by application and by country, revenue for each segment.

Chapter 9: Europe by type, by application and by country, revenue for each segment.

Chapter 10: China type, by application, revenue for each segment.

Chapter 11: Asia (excluding China) type, by application and by region, revenue for each segment.

Chapter 12: South America, Middle East and Africa by type, by application and by country, revenue for each segment.

Chapter 13: The main concluding insights of the report.

More report detail

Tables and figures
List of Tables Table 1. Global GLP-1 Agonists for the Treatment of both Diabetes and Obesity Market Size Growth Rate by Type (US$ Million), 2021 VS 2025 VS 2032 Table 2. Tirzepatide Major Player Table 3. Semaglutide Major Player Table 4. Liraglutide Major Player Table 5. Global GLP-1 Agonists for the Treatment of both Diabetes and Obesity Market Size Growth Rate by Application (US$ Million), 2021 VS 2025 VS 2032 Table 6. Retail Pharmacies Major Player Table 7. Hospital and Clinic Major Player Table 8. Other Major Player Table 9. GLP-1 Agonists for the Treatment of both Diabetes and Obesity Industry Trends Table 10. GLP-1 Agonists for the Treatment of both Diabetes and Obesity Industry Drivers Table 11. GLP-1 Agonists for the Treatment of both Diabetes and Obesity Industry Opportunities and Challenges Table 12. GLP-1 Agonists for the Treatment of both Diabetes and Obesity Industry Restraints Table 13. Global GLP-1 Agonists for the Treatment of both Diabetes and Obesity Market Size Growth Rate (CAGR) by Region (US$ Million): 2021 VS 2025 VS 2032 Table 14. Global GLP-1 Agonists for the Treatment of both Diabetes and Obesity Market Size by Region (2021-2026) & (US$ Million) Table 15. Global GLP-1 Agonists for the Treatment of both Diabetes and Obesity Market Share by Region (2021-2026) Table 16. Global GLP-1 Agonists for the Treatment of both Diabetes and Obesity Market Size by Region (2027-2032) & (US$ Million) Table 17. Global GLP-1 Agonists for the Treatment of both Diabetes and Obesity Market Share by Region (2027-2032) Table 18. Global GLP-1 Agonists for the Treatment of both Diabetes and Obesity Revenue by Players (US$ Million) & (2021-2026) Table 19. Global GLP-1 Agonists for the Treatment of both Diabetes and Obesity Revenue Market Share by Players (2021-2026) Table 20. Global GLP-1 Agonists for the Treatment of both Diabetes and Obesity Key Players Ranking, 2024 VS 2025 VS 2026 Table 21. Global GLP-1 Agonists for the Treatment of both Diabetes and Obesity Key Players Headquarters & Area Served Table 22. Global GLP-1 Agonists for the Treatment of both Diabetes and Obesity Players, Product Type & Application Table 23. Global GLP-1 Agonists for the Treatment of both Diabetes and Obesity Players Establishment Date Table 24. Global Players Market Concentration Ratio (CR5 and HHI) Table 25. Global GLP-1 Agonists for the Treatment of both Diabetes and Obesity by Players Type (Tier 1, Tier 2, and Tier 3) & (Based on the Revenue of 2025) Table 26. Global GLP-1 Agonists for the Treatment of both Diabetes and Obesity Revenue by Type 2021 VS 2025 VS 2032 (US$ Million) Table 27. Global GLP-1 Agonists for the Treatment of both Diabetes and Obesity Revenue by Type (2021-2026) & (US$ Million) Table 28. Global GLP-1 Agonists for the Treatment of both Diabetes and Obesity Revenue by Type (2027-2032) & (US$ Million) Table 29. Global GLP-1 Agonists for the Treatment of both Diabetes and Obesity Revenue Market Share by Type (2021-2026) Table 30. Global GLP-1 Agonists for the Treatment of both Diabetes and Obesity Revenue Market Share by Type (2027-2032) Table 31. Global GLP-1 Agonists for the Treatment of both Diabetes and Obesity Revenue by Application 2021 VS 2025 VS 2032 (US$ Million) Table 32. Global GLP-1 Agonists for the Treatment of both Diabetes and Obesity Revenue by Application (2021-2026) & (US$ Million) Table 33. Global GLP-1 Agonists for the Treatment of both Diabetes and Obesity Revenue by Application (2027-2032) & (US$ Million) Table 34. Global GLP-1 Agonists for the Treatment of both Diabetes and Obesity Revenue Market Share by Application (2021-2026) Table 35. Global GLP-1 Agonists for the Treatment of both Diabetes and Obesity Revenue Market Share by Application (2027-2032) Table 36. Novo Nordisk Company Information Table 37. Novo Nordisk Business Overview Table 38. Novo Nordisk GLP-1 Agonists for the Treatment of both Diabetes and Obesity Revenue and Gross Margin (US$ Million) & (2021-2026) Table 39. Novo Nordisk GLP-1 Agonists for the Treatment of both Diabetes and Obesity Product Portfolio Table 40. Novo Nordisk Recent Development Table 41. Eli Lilly Company Information Table 42. Eli Lilly Business Overview Table 43. Eli Lilly GLP-1 Agonists for the Treatment of both Diabetes and Obesity Revenue and Gross Margin (US$ Million) & (2021-2026) Table 44. Eli Lilly GLP-1 Agonists for the Treatment of both Diabetes and Obesity Product Portfolio Table 45. Eli Lilly Recent Development Table 46. North America GLP-1 Agonists for the Treatment of both Diabetes and Obesity Revenue by Type (2021-2026) & (US$ Million) Table 47. North America GLP-1 Agonists for the Treatment of both Diabetes and Obesity Revenue by Type (2027-2032) & (US$ Million) Table 48. North America GLP-1 Agonists for the Treatment of both Diabetes and Obesity Revenue by Application (2021-2026) & (US$ Million) Table 49. North America GLP-1 Agonists for the Treatment of both Diabetes and Obesity Revenue by Application (2027-2032) & (US$ Million) Table 50. North America GLP-1 Agonists for the Treatment of both Diabetes and Obesity Revenue by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 51. North America GLP-1 Agonists for the Treatment of both Diabetes and Obesity Revenue by Country (2021-2026) & (US$ Million) Table 52. North America GLP-1 Agonists for the Treatment of both Diabetes and Obesity Revenue by Country (US$ Million) & (2027-2032) Table 53. Europe GLP-1 Agonists for the Treatment of both Diabetes and Obesity Revenue by Type (2021-2026) & (US$ Million) Table 54. Europe GLP-1 Agonists for the Treatment of both Diabetes and Obesity Revenue by Type (2027-2032) & (US$ Million) Table 55. Europe GLP-1 Agonists for the Treatment of both Diabetes and Obesity Revenue by Application (2021-2026) & (US$ Million) Table 56. Europe GLP-1 Agonists for the Treatment of both Diabetes and Obesity Revenue by Application (2027-2032) & (US$ Million) Table 57. Europe GLP-1 Agonists for the Treatment of both Diabetes and Obesity Revenue by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 58. Europe GLP-1 Agonists for the Treatment of both Diabetes and Obesity Revenue by Country (2021-2026) & (US$ Million) Table 59. Europe GLP-1 Agonists for the Treatment of both Diabetes and Obesity Revenue by Country (US$ Million) & (2027-2032) Table 60. China GLP-1 Agonists for the Treatment of both Diabetes and Obesity Revenue by Type (2021-2026) & (US$ Million) Table 61. China GLP-1 Agonists for the Treatment of both Diabetes and Obesity Revenue by Type (2027-2032) & (US$ Million) Table 62. China GLP-1 Agonists for the Treatment of both Diabetes and Obesity Revenue by Application (2021-2026) & (US$ Million) Table 63. China GLP-1 Agonists for the Treatment of both Diabetes and Obesity Revenue by Application (2027-2032) & (US$ Million) Table 64. Asia GLP-1 Agonists for the Treatment of both Diabetes and Obesity Revenue by Type (2021-2026) & (US$ Million) Table 65. Asia GLP-1 Agonists for the Treatment of both Diabetes and Obesity Revenue by Type (2027-2032) & (US$ Million) Table 66. Asia GLP-1 Agonists for the Treatment of both Diabetes and Obesity Revenue by Application (2021-2026) & (US$ Million) Table 67. Asia GLP-1 Agonists for the Treatment of both Diabetes and Obesity Revenue by Application (2027-2032) & (US$ Million) Table 68. Asia GLP-1 Agonists for the Treatment of both Diabetes and Obesity Revenue by Region (2021 VS 2025 VS 2032) & (US$ Million) Table 69. Asia GLP-1 Agonists for the Treatment of both Diabetes and Obesity Revenue by Region (US$ Million) & (2021-2026) Table 70. Asia GLP-1 Agonists for the Treatment of both Diabetes and Obesity Revenue by Region (US$ Million) & (2027-2032) Table 71. SAMEA GLP-1 Agonists for the Treatment of both Diabetes and Obesity Revenue by Type (2021-2026) & (US$ Million) Table 72. SAMEA GLP-1 Agonists for the Treatment of both Diabetes and Obesity Revenue by Type (2027-2032) & (US$ Million) Table 73. SAMEA GLP-1 Agonists for the Treatment of both Diabetes and Obesity Revenue by Application (2021-2026) & (US$ Million) Table 74. SAMEA GLP-1 Agonists for the Treatment of both Diabetes and Obesity Revenue by Application (2027-2032) & (US$ Million) Table 75. SAMEA GLP-1 Agonists for the Treatment of both Diabetes and Obesity Revenue by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 76. SAMEA GLP-1 Agonists for the Treatment of both Diabetes and Obesity Revenue by Country (2021-2026) & (US$ Million) Table 77. SAMEA GLP-1 Agonists for the Treatment of both Diabetes and Obesity Revenue by Country (US$ Million) & (2027-2032) Table 78. Research Programs/Design for This Report Table 79. Authors List of This Report Table 80. Secondary Sources Table 81. Primary Sources List of Figures Figure 1. GLP-1 Agonists for the Treatment of both Diabetes and Obesity Image Figure 2. Global GLP-1 Agonists for the Treatment of both Diabetes and Obesity Market Size Growth Rate by Type (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global GLP-1 Agonists for the Treatment of both Diabetes and Obesity Market Size Share 2021 VS 2025 VS 2032 Figure 4. Tirzepatide Image Figure 5. Semaglutide Image Figure 6. Liraglutide Image Figure 7. Global GLP-1 Agonists for the Treatment of both Diabetes and Obesity Market Size Growth Rate by Application (US$ Million), 2021 VS 2025 VS 2032 Figure 8. Global GLP-1 Agonists for the Treatment of both Diabetes and Obesity Market Size Share 2021 VS 2025 VS 2032 Figure 9. Retail Pharmacies Image Figure 10. Hospital and Clinic Image Figure 11. Other Image Figure 12. Global GLP-1 Agonists for the Treatment of both Diabetes and Obesity Market Size (US$ Million) & (2021-2032) Figure 13. Global GLP-1 Agonists for the Treatment of both Diabetes and Obesity Market Size, (US$ Million), 2021 VS 2025 VS 2032 Figure 14. Global GLP-1 Agonists for the Treatment of both Diabetes and Obesity Market Share by Region: 2021 VS 2025 VS 2032 Figure 15. Global GLP-1 Agonists for the Treatment of both Diabetes and Obesity Players Revenue Share Top 10 and Top 5 in 2025 Figure 16. Players Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 17. Global GLP-1 Agonists for the Treatment of both Diabetes and Obesity Revenue by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 18. Global GLP-1 Agonists for the Treatment of both Diabetes and Obesity Revenue Market Share 2021 VS 2025 VS 2032 Figure 19. Global GLP-1 Agonists for the Treatment of both Diabetes and Obesity Revenue Market Share by Type (2021-2032) Figure 20. Global GLP-1 Agonists for the Treatment of both Diabetes and Obesity Revenue by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 21. Global GLP-1 Agonists for the Treatment of both Diabetes and Obesity Revenue Market Share by Application (2021 VS 2025 VS 2032) Figure 22. Global GLP-1 Agonists for the Treatment of both Diabetes and Obesity Revenue Market Share by Application (2021-2032) Figure 23. North America GLP-1 Agonists for the Treatment of both Diabetes and Obesity Revenue YoY Growth (2021-2032) & (US$ Million) Figure 24. North America GLP-1 Agonists for the Treatment of both Diabetes and Obesity Revenue Share by Type (2021-2032) Figure 25. North America GLP-1 Agonists for the Treatment of both Diabetes and Obesity Revenue Share by Application (2021-2032) Figure 26. North America GLP-1 Agonists for the Treatment of both Diabetes and Obesity Revenue Share by Country (2021-2032) Figure 27. United States GLP-1 Agonists for the Treatment of both Diabetes and Obesity Revenue YoY Growth (US$ Million) & (2021-2032) Figure 28. Canada GLP-1 Agonists for the Treatment of both Diabetes and Obesity Revenue YoY Growth (US$ Million) & (2021-2032) Figure 29. Mexico GLP-1 Agonists for the Treatment of both Diabetes and Obesity Revenue YoY Growth (US$ Million) & (2021-2032) Figure 30. Europe GLP-1 Agonists for the Treatment of both Diabetes and Obesity Revenue YoY Growth (2021-2032) & (US$ Million) Figure 31. Europe GLP-1 Agonists for the Treatment of both Diabetes and Obesity Revenue Share by Type (2021-2032) Figure 32. Europe GLP-1 Agonists for the Treatment of both Diabetes and Obesity Revenue Share by Application (2021-2032) Figure 33. Europe GLP-1 Agonists for the Treatment of both Diabetes and Obesity Revenue Share by Country (2021-2032) Figure 34. Germany GLP-1 Agonists for the Treatment of both Diabetes and Obesity Revenue YoY Growth (US$ Million) & (2021-2032) Figure 35. France GLP-1 Agonists for the Treatment of both Diabetes and Obesity Revenue YoY Growth (US$ Million) & (2021-2032) Figure 36. U.K. GLP-1 Agonists for the Treatment of both Diabetes and Obesity Revenue YoY Growth (US$ Million) & (2021-2032) Figure 37. Italy GLP-1 Agonists for the Treatment of both Diabetes and Obesity Revenue YoY Growth (US$ Million) & (2021-2032) Figure 38. Spain GLP-1 Agonists for the Treatment of both Diabetes and Obesity Revenue YoY Growth (US$ Million) & (2021-2032) Figure 39. Russia GLP-1 Agonists for the Treatment of both Diabetes and Obesity Revenue YoY Growth (US$ Million) & (2021-2032) Figure 40. Netherlands GLP-1 Agonists for the Treatment of both Diabetes and Obesity Revenue YoY Growth (US$ Million) & (2021-2032) Figure 41. Nordic Countries GLP-1 Agonists for the Treatment of both Diabetes and Obesity Revenue YoY Growth (US$ Million) & (2021-2032) Figure 42. China GLP-1 Agonists for the Treatment of both Diabetes and Obesity Revenue YoY Growth (2021-2032) & (US$ Million) Figure 43. China GLP-1 Agonists for the Treatment of both Diabetes and Obesity Revenue Share by Type (2021-2032) Figure 44. China GLP-1 Agonists for the Treatment of both Diabetes and Obesity Revenue Share by Application (2021-2032) Figure 45. Asia GLP-1 Agonists for the Treatment of both Diabetes and Obesity Revenue YoY Growth (2021-2032) & (US$ Million) Figure 46. Asia GLP-1 Agonists for the Treatment of both Diabetes and Obesity Revenue Share by Type (2021-2032) Figure 47. Asia GLP-1 Agonists for the Treatment of both Diabetes and Obesity Revenue Share by Application (2021-2032) Figure 48. Asia GLP-1 Agonists for the Treatment of both Diabetes and Obesity Revenue Share by Region (2021-2032) Figure 49. Japan GLP-1 Agonists for the Treatment of both Diabetes and Obesity Revenue YoY Growth (US$ Million) & (2021-2032) Figure 50. South Korea GLP-1 Agonists for the Treatment of both Diabetes and Obesity Revenue YoY Growth (US$ Million) & (2021-2032) Figure 51. India GLP-1 Agonists for the Treatment of both Diabetes and Obesity Revenue YoY Growth (US$ Million) & (2021-2032) Figure 52. Australia GLP-1 Agonists for the Treatment of both Diabetes and Obesity Revenue YoY Growth (US$ Million) & (2021-2032) Figure 53. Taiwan GLP-1 Agonists for the Treatment of both Diabetes and Obesity Revenue YoY Growth (US$ Million) & (2021-2032) Figure 54. Southeast Asia GLP-1 Agonists for the Treatment of both Diabetes and Obesity Revenue YoY Growth (US$ Million) & (2021-2032) Figure 55. SAMEA GLP-1 Agonists for the Treatment of both Diabetes and Obesity Revenue YoY Growth (2021-2032) & (US$ Million) Figure 56. SAMEA GLP-1 Agonists for the Treatment of both Diabetes and Obesity Revenue Share by Type (2021-2032) Figure 57. SAMEA GLP-1 Agonists for the Treatment of both Diabetes and Obesity Revenue Share by Application (2021-2032) Figure 58. SAMEA GLP-1 Agonists for the Treatment of both Diabetes and Obesity Revenue Share by Country (2021-2032) Figure 59. Brazil GLP-1 Agonists for the Treatment of both Diabetes and Obesity Revenue YoY Growth (US$ Million) & (2021-2032) Figure 60. Argentina GLP-1 Agonists for the Treatment of both Diabetes and Obesity Revenue YoY Growth (US$ Million) & (2021-2032) Figure 61. Chile GLP-1 Agonists for the Treatment of both Diabetes and Obesity Revenue YoY Growth (US$ Million) & (2021-2032) Figure 62. Colombia GLP-1 Agonists for the Treatment of both Diabetes and Obesity Revenue YoY Growth (US$ Million) & (2021-2032) Figure 63. Peru GLP-1 Agonists for the Treatment of both Diabetes and Obesity Revenue YoY Growth (US$ Million) & (2021-2032) Figure 64. Saudi Arabia GLP-1 Agonists for the Treatment of both Diabetes and Obesity Revenue YoY Growth (US$ Million) & (2021-2032) Figure 65. Israel GLP-1 Agonists for the Treatment of both Diabetes and Obesity Revenue YoY Growth (US$ Million) & (2021-2032) Figure 66. UAE GLP-1 Agonists for the Treatment of both Diabetes and Obesity Revenue YoY Growth (US$ Million) & (2021-2032) Figure 67. Turkey GLP-1 Agonists for the Treatment of both Diabetes and Obesity Revenue YoY Growth (US$ Million) & (2021-2032) Figure 68. Iran GLP-1 Agonists for the Treatment of both Diabetes and Obesity Revenue YoY Growth (US$ Million) & (2021-2032) Figure 69. Egypt GLP-1 Agonists for the Treatment of both Diabetes and Obesity Revenue YoY Growth (US$ Million) & (2021-2032) Figure 70. Years Considered Figure 71. Research Process Figure 72. Key Executives Interviewed

Scope & coverage.

Types
  • Tirzepatide
  • Semaglutide
  • Liraglutide
Applications
  • Retail Pharmacies
  • Hospital and Clinic
  • Other
Companies covered
  • Novo Nordisk
  • Eli Lilly

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 GLP-1 Agonists for the Treatment of both Diabetes and Obesity Market by Type
  3. 1.2.1 Global GLP-1 Agonists for the Treatment of both Diabetes and Obesity Market Size by Type, 2021 VS 2025 VS 2032
  4. 1.2.2 Tirzepatide
  5. 1.2.3 Semaglutide
  6. 1.2.4 Liraglutide
  7. 1.3 GLP-1 Agonists for the Treatment of both Diabetes and Obesity Market by Application
  8. 1.3.1 Global GLP-1 Agonists for the Treatment of both Diabetes and Obesity Market Size by Application, 2021 VS 2025 VS 2032
  9. 1.3.2 Retail Pharmacies
  10. 1.3.3 Hospital and Clinic
  11. 1.3.4 Other
  12. 1.4 Assumptions and Limitations
  13. 1.5 Study Goals and Objectives
2 GLP-1 Agonists for the Treatment of both Diabetes and Obesity Market Dynamics
  1. 2.1 GLP-1 Agonists for the Treatment of both Diabetes and Obesity Industry Trends
  2. 2.2 GLP-1 Agonists for the Treatment of both Diabetes and Obesity Industry Drivers
  3. 2.3 GLP-1 Agonists for the Treatment of both Diabetes and Obesity Industry Opportunities and Challenges
  4. 2.4 GLP-1 Agonists for the Treatment of both Diabetes and Obesity Industry Restraints
3 Global Growth Perspective
  1. 3.1 Global GLP-1 Agonists for the Treatment of both Diabetes and Obesity Market Perspective (2021-2032)
  2. 3.2 Global GLP-1 Agonists for the Treatment of both Diabetes and Obesity Growth Trends by Region
  3. 3.2.1 Global GLP-1 Agonists for the Treatment of both Diabetes and Obesity Market Size by Region: 2021 VS 2025 VS 2032
  4. 3.2.2 Global GLP-1 Agonists for the Treatment of both Diabetes and Obesity Market Size by Region (2021-2026)
  5. 3.2.3 Global GLP-1 Agonists for the Treatment of both Diabetes and Obesity Market Size by Region (2027-2032)
4 Competitive Landscape by Players
  1. 4.1 Global GLP-1 Agonists for the Treatment of both Diabetes and Obesity Revenue by Players
  2. 4.1.1 Global GLP-1 Agonists for the Treatment of both Diabetes and Obesity Revenue by Players (2021-2026)
  3. 4.1.2 Global GLP-1 Agonists for the Treatment of both Diabetes and Obesity Revenue Market Share by Players (2021-2026)
  4. 4.1.3 Global GLP-1 Agonists for the Treatment of both Diabetes and Obesity Players Revenue Share Top 10 and Top 5 in 2025
  5. 4.2 Global GLP-1 Agonists for the Treatment of both Diabetes and Obesity Key Players Ranking, 2024 VS 2025 VS 2026
  6. 4.3 Global GLP-1 Agonists for the Treatment of both Diabetes and Obesity Key Players Headquarters & Area Served
  7. 4.4 Global GLP-1 Agonists for the Treatment of both Diabetes and Obesity Players, Product Type & Application
  8. 4.5 Global GLP-1 Agonists for the Treatment of both Diabetes and Obesity Players Establishment Date
  9. 4.6 Market Competitive Analysis
  10. 4.6.1 Global GLP-1 Agonists for the Treatment of both Diabetes and Obesity Market CR5 and HHI
  11. 4.6.3 2025 GLP-1 Agonists for the Treatment of both Diabetes and Obesity Tier 1, Tier 2, and Tier 3
5 GLP-1 Agonists for the Treatment of both Diabetes and Obesity Market Size by Type
  1. 5.1 Global GLP-1 Agonists for the Treatment of both Diabetes and Obesity Revenue by Type (2021 VS 2025 VS 2032)
  2. 5.2 Global GLP-1 Agonists for the Treatment of both Diabetes and Obesity Revenue by Type (2021-2032)
  3. 5.3 Global GLP-1 Agonists for the Treatment of both Diabetes and Obesity Revenue Market Share by Type (2021-2032)
6 GLP-1 Agonists for the Treatment of both Diabetes and Obesity Market Size by Application
  1. 6.1 Global GLP-1 Agonists for the Treatment of both Diabetes and Obesity Revenue by Application (2021 VS 2025 VS 2032)
  2. 6.2 Global GLP-1 Agonists for the Treatment of both Diabetes and Obesity Revenue by Application (2021-2032)
  3. 6.3 Global GLP-1 Agonists for the Treatment of both Diabetes and Obesity Revenue Market Share by Application (2021-2032)
7 Company Profiles
  1. 7.1 Novo Nordisk
  2. 7.1.1 Novo Nordisk Company Information
  3. 7.1.2 Novo Nordisk Business Overview
  4. 7.1.3 Novo Nordisk GLP-1 Agonists for the Treatment of both Diabetes and Obesity Revenue and Gross Margin (2021-2026)
  5. 7.1.4 Novo Nordisk GLP-1 Agonists for the Treatment of both Diabetes and Obesity Product Portfolio
  6. 7.1.5 Novo Nordisk Recent Developments
  7. 7.2 Eli Lilly
  8. 7.2.1 Eli Lilly Company Information
  9. 7.2.2 Eli Lilly Business Overview
  10. 7.2.3 Eli Lilly GLP-1 Agonists for the Treatment of both Diabetes and Obesity Revenue and Gross Margin (2021-2026)
  11. 7.2.4 Eli Lilly GLP-1 Agonists for the Treatment of both Diabetes and Obesity Product Portfolio
  12. 7.2.5 Eli Lilly Recent Developments
8 North America
  1. 8.1 North America GLP-1 Agonists for the Treatment of both Diabetes and Obesity Revenue (2021-2032)
  2. 8.2 North America GLP-1 Agonists for the Treatment of both Diabetes and Obesity Revenue by Type (2021-2032)
  3. 8.2.1 North America GLP-1 Agonists for the Treatment of both Diabetes and Obesity Revenue by Type (2021-2026)
  4. 8.2.2 North America GLP-1 Agonists for the Treatment of both Diabetes and Obesity Revenue by Type (2027-2032)
  5. 8.3 North America GLP-1 Agonists for the Treatment of both Diabetes and Obesity Revenue Share by Type (2021-2032)
  6. 8.4 North America GLP-1 Agonists for the Treatment of both Diabetes and Obesity Revenue by Application (2021-2032)
  7. 8.4.1 North America GLP-1 Agonists for the Treatment of both Diabetes and Obesity Revenue by Application (2021-2026)
  8. 8.4.2 North America GLP-1 Agonists for the Treatment of both Diabetes and Obesity Revenue by Application (2027-2032)
  9. 8.5 North America GLP-1 Agonists for the Treatment of both Diabetes and Obesity Revenue Share by Application (2021-2032)
  10. 8.6 North America GLP-1 Agonists for the Treatment of both Diabetes and Obesity Revenue by Country
  11. 8.6.1 North America GLP-1 Agonists for the Treatment of both Diabetes and Obesity Revenue by Country (2021 VS 2025 VS 2032)
  12. 8.6.2 North America GLP-1 Agonists for the Treatment of both Diabetes and Obesity Revenue by Country (2021-2026)
  13. 8.6.3 North America GLP-1 Agonists for the Treatment of both Diabetes and Obesity Revenue by Country (2027-2032)
  14. 8.6.4 United States
  15. 8.6.5 Canada
  16. 8.6.6 Mexico
9 Europe
  1. 9.1 Europe GLP-1 Agonists for the Treatment of both Diabetes and Obesity Revenue (2021-2032)
  2. 9.2 Europe GLP-1 Agonists for the Treatment of both Diabetes and Obesity Revenue by Type (2021-2032)
  3. 9.2.1 Europe GLP-1 Agonists for the Treatment of both Diabetes and Obesity Revenue by Type (2021-2026)
  4. 9.2.2 Europe GLP-1 Agonists for the Treatment of both Diabetes and Obesity Revenue by Type (2027-2032)
  5. 9.3 Europe GLP-1 Agonists for the Treatment of both Diabetes and Obesity Revenue Share by Type (2021-2032)
  6. 9.4 Europe GLP-1 Agonists for the Treatment of both Diabetes and Obesity Revenue by Application (2021-2032)
  7. 9.4.1 Europe GLP-1 Agonists for the Treatment of both Diabetes and Obesity Revenue by Application (2021-2026)
  8. 9.4.2 Europe GLP-1 Agonists for the Treatment of both Diabetes and Obesity Revenue by Application (2027-2032)
  9. 9.5 Europe GLP-1 Agonists for the Treatment of both Diabetes and Obesity Revenue Share by Application (2021-2032)
  10. 9.6 Europe GLP-1 Agonists for the Treatment of both Diabetes and Obesity Revenue by Country
  11. 9.6.1 Europe GLP-1 Agonists for the Treatment of both Diabetes and Obesity Revenue by Country (2021 VS 2025 VS 2032)
  12. 9.6.2 Europe GLP-1 Agonists for the Treatment of both Diabetes and Obesity Revenue by Country (2021-2026)
  13. 9.6.3 Europe GLP-1 Agonists for the Treatment of both Diabetes and Obesity Revenue by Country (2027-2032)
  14. 9.6.4 Germany
  15. 9.6.5 France
  16. 9.6.6 U.K.
  17. 9.6.7 Italy
  18. 9.6.8 Russia
  19. 9.6.9 Spain
  20. 9.6.10 Netherlands
  21. 9.6.11 Switzerland
  22. 9.6.12 Sweden
  23. 9.6.13 Poland
10 China
  1. 10.1 China GLP-1 Agonists for the Treatment of both Diabetes and Obesity Revenue (2021-2032)
  2. 10.2 China GLP-1 Agonists for the Treatment of both Diabetes and Obesity Revenue by Type (2021-2032)
  3. 10.2.1 China GLP-1 Agonists for the Treatment of both Diabetes and Obesity Revenue by Type (2021-2026)
  4. 10.2.2 China GLP-1 Agonists for the Treatment of both Diabetes and Obesity Revenue by Type (2027-2032)
  5. 10.3 China GLP-1 Agonists for the Treatment of both Diabetes and Obesity Revenue Share by Type (2021-2032)
  6. 10.4 China GLP-1 Agonists for the Treatment of both Diabetes and Obesity Revenue by Application (2021-2032)
  7. 10.4.1 China GLP-1 Agonists for the Treatment of both Diabetes and Obesity Revenue by Application (2021-2026)
  8. 10.4.2 China GLP-1 Agonists for the Treatment of both Diabetes and Obesity Revenue by Application (2027-2032)
  9. 10.5 China GLP-1 Agonists for the Treatment of both Diabetes and Obesity Revenue Share by Application (2021-2032)
11 Asia (Excluding China)
  1. 11.1 Asia GLP-1 Agonists for the Treatment of both Diabetes and Obesity Revenue (2021-2032)
  2. 11.2 Asia GLP-1 Agonists for the Treatment of both Diabetes and Obesity Revenue by Type (2021-2032)
  3. 11.2.1 Asia GLP-1 Agonists for the Treatment of both Diabetes and Obesity Revenue by Type (2021-2026)
  4. 11.2.2 Asia GLP-1 Agonists for the Treatment of both Diabetes and Obesity Revenue by Type (2027-2032)
  5. 11.3 Asia GLP-1 Agonists for the Treatment of both Diabetes and Obesity Revenue Share by Type (2021-2032)
  6. 11.4 Asia GLP-1 Agonists for the Treatment of both Diabetes and Obesity Revenue by Application (2021-2032)
  7. 11.4.1 Asia GLP-1 Agonists for the Treatment of both Diabetes and Obesity Revenue by Application (2021-2026)
  8. 11.4.2 Asia GLP-1 Agonists for the Treatment of both Diabetes and Obesity Revenue by Application (2027-2032)
  9. 11.5 Asia GLP-1 Agonists for the Treatment of both Diabetes and Obesity Revenue Share by Application (2021-2032)
  10. 11.6 Asia GLP-1 Agonists for the Treatment of both Diabetes and Obesity Revenue by Country
  11. 11.6.1 Asia GLP-1 Agonists for the Treatment of both Diabetes and Obesity Revenue by Country (2021 VS 2025 VS 2032)
  12. 11.6.2 Asia GLP-1 Agonists for the Treatment of both Diabetes and Obesity Revenue by Country (2021-2026)
  13. 11.6.3 Asia GLP-1 Agonists for the Treatment of both Diabetes and Obesity Revenue by Country (2027-2032)
  14. 11.6.4 Japan
  15. 11.6.5 South Korea
  16. 11.6.6 India
  17. 11.6.7 Australia
  18. 11.6.8 Taiwan
  19. 11.6.9 Southeast Asia
12 South America, Middle East and Africa
  1. 12.1 SAMEA GLP-1 Agonists for the Treatment of both Diabetes and Obesity Revenue (2021-2032)
  2. 12.2 SAMEA GLP-1 Agonists for the Treatment of both Diabetes and Obesity Revenue by Type (2021-2032)
  3. 12.2.1 SAMEA GLP-1 Agonists for the Treatment of both Diabetes and Obesity Revenue by Type (2021-2026)
  4. 12.2.2 SAMEA GLP-1 Agonists for the Treatment of both Diabetes and Obesity Revenue by Type (2027-2032)
  5. 12.3 SAMEA GLP-1 Agonists for the Treatment of both Diabetes and Obesity Revenue Share by Type (2021-2032)
  6. 12.4 SAMEA GLP-1 Agonists for the Treatment of both Diabetes and Obesity Revenue by Application (2021-2032)
  7. 12.4.1 SAMEA GLP-1 Agonists for the Treatment of both Diabetes and Obesity Revenue by Application (2021-2026)
  8. 12.4.2 SAMEA GLP-1 Agonists for the Treatment of both Diabetes and Obesity Revenue by Application (2027-2032)
  9. 12.5 SAMEA GLP-1 Agonists for the Treatment of both Diabetes and Obesity Revenue Share by Application (2021-2032)
  10. 12.6 SAMEA GLP-1 Agonists for the Treatment of both Diabetes and Obesity Revenue by Country
  11. 12.6.1 SAMEA GLP-1 Agonists for the Treatment of both Diabetes and Obesity Revenue by Country (2021 VS 2025 VS 2032)
  12. 12.6.2 SAMEA GLP-1 Agonists for the Treatment of both Diabetes and Obesity Revenue by Country (2021-2026)
  13. 12.6.3 SAMEA GLP-1 Agonists for the Treatment of both Diabetes and Obesity Revenue by Country (2027-2032)
  14. 12.6.4 Brazil
  15. 12.6.5 Argentina
  16. 12.6.6 Chile
  17. 12.6.7 Colombia
  18. 12.6.8 Peru
  19. 12.6.9 Saudi Arabia
  20. 12.6.10 Israel
  21. 12.6.11 UAE
  22. 12.6.12 Turkey
  23. 12.6.13 Iran
  24. 12.6.14 Egypt
13 Concluding Insights
    14 Appendix
    1. 14.1 Reasons for Doing This Study
    2. 14.2 Research Methodology
    3. 14.3 Research Process
    4. 14.4 Authors List of This Report
    5. 14.5 Data Source
    6. 14.5.1 Secondary Sources
    7. 14.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,950USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst